Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

uindicator Dec. 20 at 3:03 PM

$BCTX what’s the overall view or potential of the therapy? I see fda results coming up soon

1 · Reply

ManuTa Dec. 20 at 5:57 AM

$BCTX question is 1. Pump & offering or 2. offering and pump ?

0 · Reply

SmallCapGrowth Dec. 18 at 7:33 PM

Small Cap Stock Alert: $BCTX BriaCell’s - HOT HOT PENNY https://investorshangout.com/post/view?id=6807650

0 · Reply

SmallCapGrowth Dec. 18 at 7:31 PM

Small Cap Stock Alert: $BCTX BriaCell’s - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6807647

0 · Reply

SmallCapGrowth Dec. 18 at 6:10 PM

Nature Medicine highlights BriaCell’s Phase 3 metastatic breast cancer trial as one of the “11 clinical trials that will shape medicine in 2026.” Top line data expected as early as H1 2026. $BCTX featured as a clinical trial to watch. NEWS: https://globenewswire.com/news-release/2025/12/18/3207604/0/en/Eleven-clinical-trials-that-will-shape-medicine-in-2026-BriaCell-Phase-3-Trial-Featured-in-Nature-Medicine.html

0 · Reply

SmallCapGrowth Dec. 18 at 5:20 PM

Small Cap Stock Alert: $BCTX BriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026” in Nature Medicine. “Eleven clinical trials that will shape medicine in 2026” BriaCell anticipates reporting top line data as early as H1-2026. NEWS: https://globenewswire.com/news-release/2025/12/18/3207604/0/en/Eleven-clinical-trials-that-will-shape-medicine-in-2026-BriaCell-Phase-3-Trial-Featured-in-Nature-Medicine.html #BCTX #STOCKSTOBUY #STOCKSTOWATCH #TEAMHIGHALERT #STOCKS

0 · Reply

SmallCapGrowth Dec. 18 at 4:27 PM

MOMO'S BREAKOUT BOARD : Cancer Stock News Alert: $BCTX Phase 3 T... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177080364 via @Investors_Hub

0 · Reply

SmallCapGrowth Dec. 18 at 3:59 PM

Cancer Stock News Alert: $BCTX Phase 3 Trial Featured in Nature Medicine - “Eleven clinical trials that will shape medicine in 2026” BriaCell anticipates reporting top line data as early as H1-2026 $BCTX featured as a clinical trial to watch. NEWS: https://globenewswire.com/news-release/2025/12/18/3207604/0/en/Eleven-clinical-trials-that-will-shape-medicine-in-2026-BriaCell-Phase-3-Trial-Featured-in-Nature-Medicine.html

0 · Reply

SmallCapGrowth Dec. 18 at 3:09 PM

0 · Reply

SmallCapGrowth Dec. 18 at 3:04 PM

0 · Reply

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 10, 2025, 7:30 AM EST - 11 days ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 9, 2025, 7:30 AM EST - 12 days ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 2, 2025, 7:30 AM EST - 19 days ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 26 days ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 4 weeks ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 4 weeks ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 6 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 6 weeks ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 22, 2025, 7:30 AM EDT - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Oct 21, 2025, 7:50 AM EDT - 2 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 2 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 2 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 2 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 2 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 4 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 4 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 4 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 4 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 5 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 5 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 5 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 5 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 5 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 5 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 5 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 5 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 5 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 5 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 6 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 7 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 7 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 7 months ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell CEO Letter to Shareholders

Apr 30, 2025, 7:30 AM EDT - 8 months ago

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Apr 28, 2025, 4:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Closing of $13.8 million Public Offering

Apr 28, 2025, 7:30 AM EDT - 8 months ago

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Apr 24, 2025, 8:00 PM EDT - 8 months ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 10:11 AM EDT - 8 months ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 7:30 AM EDT - 8 months ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 23, 2025, 7:30 AM EDT - 8 months ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 22, 2025, 7:30 AM EDT - 8 months ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 16, 2025, 7:30 AM EDT - 8 months ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Mar 26, 2025, 8:00 AM EDT - 9 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 20, 2025, 8:00 AM EDT - 9 months ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Feb 5, 2025, 6:15 PM EST - 11 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 4:05 PM EST - 11 months ago

BriaCell Therapeutics Announces Closing of Public Offering

uindicator Dec. 20 at 3:03 PM

$BCTX what’s the overall view or potential of the therapy? I see fda results coming up soon

1 · Reply

ManuTa Dec. 20 at 5:57 AM

$BCTX question is 1. Pump & offering or 2. offering and pump ?

0 · Reply

SmallCapGrowth Dec. 18 at 7:33 PM

Small Cap Stock Alert: $BCTX BriaCell’s - HOT HOT PENNY https://investorshangout.com/post/view?id=6807650

0 · Reply

SmallCapGrowth Dec. 18 at 7:31 PM

Small Cap Stock Alert: $BCTX BriaCell’s - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6807647

0 · Reply

SmallCapGrowth Dec. 18 at 6:10 PM

0 · Reply

SmallCapGrowth Dec. 18 at 5:20 PM

0 · Reply

SmallCapGrowth Dec. 18 at 4:27 PM

MOMO'S BREAKOUT BOARD : Cancer Stock News Alert: $BCTX Phase 3 T... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177080364 via @Investors_Hub

0 · Reply

SmallCapGrowth Dec. 18 at 3:59 PM

0 · Reply

SmallCapGrowth Dec. 18 at 3:09 PM

0 · Reply

SmallCapGrowth Dec. 18 at 3:04 PM

0 · Reply

2maligators Dec. 18 at 2:42 PM

$BCTX why don’t they want this over $13-14?

1 · Reply

SmallCapVoice Dec. 18 at 12:31 PM

Nature Medicine highlights BriaCell’s Phase 3 metastatic breast cancer trial as one of the “11 clinical trials that will shape medicine in 2026.” Top line data expected as early as H1 2026. $BCTX featured as a clinical trial to watch. https://www.globenewswire.com/news-release/2025/12/18/3207604/0/en/Eleven-clinical-trials-that-will-shape-medicine-in-2026-BriaCell-Phase-3-Trial-Featured-in-Nature-Medicine.html

0 · Reply

ProfessorDman1 Dec. 18 at 12:31 PM

$BCTX “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

1 · Reply

superguild Dec. 17 at 10:45 PM

$BCTX i see the stock went up a bit to attract some suckers then straight back down as usual.

0 · Reply

DunkenInvest Dec. 16 at 4:46 PM

$BCTX at this point I just hope this will crash under 5$, so I can get some cheep Christmas gifts. Let it go down until March, then it can go boom 🤗

2 · Reply

JediGreen Dec. 16 at 6:22 AM

$BCTX I just hope I have my extra 30 to 40k to dump into this if she starts to move around these days on google. Bullish baby.

1 · Reply

JediGreen Dec. 16 at 6:12 AM

$BCTX briacell therapeutics phase 3 completion time estimate - Google Search https://www.google.com/search?q=briacell+therapeutics+phase+3+completion+time+estimate&sca_esv=8efe466fbfa838b2&ei=_fRAaevuA5-qw8cPyM_bmQg&oq=briacell+therapeutics+phase%C2%A0&gs_lp=EhNtb2JpbGUtZ3dzLXdpei1zZXJwIh1icmlhY2VsbCB0aGVyYXBldXRpY3MgcGhhc2XCoCoCCAAyBRApGKABMgUQKRigATIGEAAYFhgeMgUQIRigATIFECEYoAEyBRAhGKABMgUQIRigATILEAAYgAQYhgMYigUyCBAAGKIEGIkFMgUQABjvBUjaSlD1CVjHHXACeAGQAQCYAWCgAdoEqgEBN7gBAcgBAPgBAZgCCaACswXCAgUQKRirAsICChApGLADGNYEGEfCAgoQABiwAxjWBBhHwgINEAAYgAQYsAMYQxiKBcICBRAAGIAEwgIQEC4YgAQY0QMYQxjHARiKBcICChAAGIAEGEMYigXCAgcQKRigARgKwgIFECEYqwKYAwCIBgGSBwM1LjSgB7QrsgcDMy40uAejBcIHBTItNi4zyAc7gAgA&sclient=mobile-gws-wiz-serp

1 · Reply

Rohtan Dec. 16 at 4:15 AM

$BCTX look at the number of shares owned by institutions. Is that not laughable? They don’t even have confidence in it.

1 · Reply

FredFlintstock Dec. 16 at 12:49 AM

$BCTX quite in here today, thats the sound of people losing their money

0 · Reply

Kirubin Dec. 15 at 6:04 PM

$BCTX where are the 🤡🤡🤡pumpers at?

0 · Reply

JediGreen Dec. 14 at 11:59 PM

$BCTX watching the The thing on my 5K$ Sony 85in 9 series TV that I made and baught from market money amassing TV. Get the darks of a OLED but the brights of a LED TV heard it’s the brightest on the market amassing TV. Love it.

0 · Reply

JediGreen Dec. 14 at 11:44 PM

$BCTX any of you guys want to get drunk and go skiing. I do. Sounds fun if I can bank out on this I’m going skiing trashed out of my mind 😆.

0 · Reply

Market Cap	16.86M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	17,900
Avg Vol	63,496
Day's Range	N/A - N/A
Shares Out	1.88M
Stochastic %K	9%
Beta	1.38
Analysts	Strong Buy
Price Target	$40.00